Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

active_not_recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
completednot_applicable

New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

NCT04691011
active_not_recruiting

Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients

NCT04860947
completed

Spinal Cord Analysis in Multiple Sclerosis

NCT03841903

Clinical Trials (3)

Showing 3 of 3 trials
NCT04691011Not Applicable

New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Completed
NCT04860947

Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients

Active Not Recruiting
NCT03841903

Spinal Cord Analysis in Multiple Sclerosis

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3